File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.canlet.2020.01.007
- Scopus: eid_2-s2.0-85078114210
- PMID: 31958485
- WOS: WOS:000518673300011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Loss of cytoskeleton protein ADD3 promotes tumor growth and angiogenesis in glioblastoma multiforme
Title | Loss of cytoskeleton protein ADD3 promotes tumor growth and angiogenesis in glioblastoma multiforme |
---|---|
Authors | |
Keywords | Adducin Actin cytoskeleton GBM Vascular endothelial growth factor Cell-matrix interaction |
Issue Date | 2020 |
Publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet |
Citation | Cancer Letters, 2020, v. 474, p. 118-126 How to Cite? |
Abstract | Adducin 3 (ADD3) is a crucial assembly factor in the actin cytoskeleton and has been found to be aberrantly expressed in various cancers, including glioblastoma multiforme (GBM). It has previously been studied in array-based studies with controversial findings as to its functional role in glioma. In microarray analyses of 452 glioma specimens, we found significant downregulation of ADD3 in GBM, but not in less malignant gliomas, compared to normal brain tissue, which suggests that its downregulation might underlie critical events during malignant progression. We also found that ADD3 was functionally dependent on cell-matrix interaction. In our in vivo study, the proliferative and angiogenic capacity of ADD3-depleted GBM cells was promoted, possibly through PCNA, while p53 and p21 expression was suppressed, and pro-angiogenic signals were induced through VEGF-VEGFR-2-mediated activation in endothelial cells. With correlative in vitro, in vivo, and clinical data, we provide compelling evidence on the putative tumor-suppressive role of ADD3 in modulating GBM growth and angiogenesis. As a preclinical study, our research offers a better understanding of the pathogenesis of glioma malignant progression for the benefit of future investigations. |
Persistent Identifier | http://hdl.handle.net/10722/280318 |
ISSN | 2023 Impact Factor: 9.1 2023 SCImago Journal Rankings: 2.595 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kiang, MYK | - |
dc.contributor.author | Zhang, P | - |
dc.contributor.author | Li, N | - |
dc.contributor.author | ZHU, Z | - |
dc.contributor.author | JIN, L | - |
dc.contributor.author | Leung, GK-K | - |
dc.date.accessioned | 2020-02-07T07:39:26Z | - |
dc.date.available | 2020-02-07T07:39:26Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Cancer Letters, 2020, v. 474, p. 118-126 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | http://hdl.handle.net/10722/280318 | - |
dc.description.abstract | Adducin 3 (ADD3) is a crucial assembly factor in the actin cytoskeleton and has been found to be aberrantly expressed in various cancers, including glioblastoma multiforme (GBM). It has previously been studied in array-based studies with controversial findings as to its functional role in glioma. In microarray analyses of 452 glioma specimens, we found significant downregulation of ADD3 in GBM, but not in less malignant gliomas, compared to normal brain tissue, which suggests that its downregulation might underlie critical events during malignant progression. We also found that ADD3 was functionally dependent on cell-matrix interaction. In our in vivo study, the proliferative and angiogenic capacity of ADD3-depleted GBM cells was promoted, possibly through PCNA, while p53 and p21 expression was suppressed, and pro-angiogenic signals were induced through VEGF-VEGFR-2-mediated activation in endothelial cells. With correlative in vitro, in vivo, and clinical data, we provide compelling evidence on the putative tumor-suppressive role of ADD3 in modulating GBM growth and angiogenesis. As a preclinical study, our research offers a better understanding of the pathogenesis of glioma malignant progression for the benefit of future investigations. | - |
dc.language | eng | - |
dc.publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet | - |
dc.relation.ispartof | Cancer Letters | - |
dc.subject | Adducin | - |
dc.subject | Actin cytoskeleton | - |
dc.subject | GBM | - |
dc.subject | Vascular endothelial growth factor | - |
dc.subject | Cell-matrix interaction | - |
dc.title | Loss of cytoskeleton protein ADD3 promotes tumor growth and angiogenesis in glioblastoma multiforme | - |
dc.type | Article | - |
dc.identifier.email | Kiang, MYK: mykiang@hku.hk | - |
dc.identifier.email | Zhang, P: pingder@hku.hk | - |
dc.identifier.email | Leung, GK-K: gkkleung@hku.hk | - |
dc.identifier.authority | Leung, GK-K=rp00522 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.canlet.2020.01.007 | - |
dc.identifier.pmid | 31958485 | - |
dc.identifier.scopus | eid_2-s2.0-85078114210 | - |
dc.identifier.hkuros | 309133 | - |
dc.identifier.volume | 474 | - |
dc.identifier.spage | 118 | - |
dc.identifier.epage | 126 | - |
dc.identifier.isi | WOS:000518673300011 | - |
dc.publisher.place | Ireland | - |
dc.identifier.issnl | 0304-3835 | - |